The abstract is read at the publisher; the summary is JClub's.
Blocking myeloid CD209–ICAM-2–ROCK1-ERM signaling restores antitumor T-cell activation and improves PD-1 blockade responses in immunologically “cold” tumor models.
- Why it matters: PD-1 immunotherapy often fails in “cold” cancers where T cells are excluded and functionally impaired, and mechanical immune suppression is not well defined.
- What they did: The study identified CD209 enrichment in tumor-infiltrating M2-like macrophages and monocytes, linked higher CD209 to poor PD-1 response, and tested CD209 blockade in mouse models and ex vivo human tumor systems.
- The result: CD209–ICAM-2 engagement increased T-cell cortical stiffness, weakened T cell–antigen presenting cell contacts, and reduced TCR signaling; disrupting this axis restored T-cell function, increased CD8+ infiltration, and overcame PD-1 resistance in refractory “cold” models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.